“…Bioactive Component Disorders References upregulation of DNMT omega-3 fatty acids: DHA, EPA colorectal cancer [25,26] folic acid colorectal cancer, breast cancer [27,28] methionine lung cancer [29] vitamin A congenital heart defects [30] DNA methyltransferase inhibition kaempferol bladder cancer [31] gallic acid lung cancer and oral cancer [32] epigallocatechin-3-gallate breast cancer, diabetic kidney disease [33,34] β-caroten colorectal cancer [35] sulforaphane breast cancer, cardiomyopathy [36,37] omega-3 fatty acids: EPA hepatocarcinoma [38] vitamin A congenital heart defects [30] histone deacetylase inhibition resveratrol breast cancer, renal cell carcinoma, colorectal cancer [39][40][41][42] apigenin prostate cancer, lung cancer [43,44] luteolin lung cancer, leukemia [45,46] chrysin melanoma [47] cinnamic acid derivatives colon and cervical cancer [48] gallic acid prostate cancer, cardiovascular diseases [49] epigallocatechin- Epigallocatechin-3-gallate (EGCG), a polyphenol member, can reduce global DNA methylation levels, DNA methyltransferase (DNMT) activity, messenger RNA (mRNA), and protein levels of DNMT1, DNMT3a, and DNMT3b. EGCG can directly inhibit the DNMT catalytic site.…”